Armata PharmaceuticalsARMP
ARMP
About: Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
Employees: 75
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
9% more funds holding
Funds holding: 23 [Q4 2024] → 25 (+2) [Q1 2025]
1.79% less ownership
Funds ownership: 3.84% [Q4 2024] → 2.05% (-1.79%) [Q1 2025]
58% less capital invested
Capital invested by funds: $2.57M [Q4 2024] → $1.08M (-$1.49M) [Q1 2025]
78% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 9
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$9
381%
upside
Avg. target
$9
381%
upside
High target
$9
381%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis | 381%upside $9 | Buy Maintained | 19 May 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
3 weeks ago
ARMP Soars 72% in a Month Following Infectious Disease Study Success
Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.
Neutral
PRNewsWire
3 weeks ago
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met AP-SA02 arm significantly improved clinical outcomes and prevented relapse compared to best available antibiotic therapy No treatment-related serious adverse events were observed with repetitive intravenous dosing LOS ANGELES , May 19, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced positive topline results from its Phase 1b/2a diSArm trial which evaluated AP-SA02, a novel intravenous ("IV") administered multi-phage therapeutic for the treatment of S taphylococcus aureus ("S. aureus") bacteremia ("SAB"), in the intent-to-treat ("ITT") population.
Negative
Zacks Investment Research
1 month ago
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates
Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.69 per share a year ago.
Neutral
PRNewsWire
1 month ago
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
LOS ANGELES , May 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2025, and provided a corporate update. First Quarter 2025 and Recent Developments: Anticipating announcement of topline results from Phase 1b/2a diSArm study of intravenous AP-SA02 as a potential treatment for Staphylococcus aureus ("S.
Negative
Zacks Investment Research
1 month ago
New Strong Sell Stocks for May 8th
ARMP, COLM and EFSI have been added to the Zacks Rank #5 (Strong Sell) List on May 8, 2025.
Neutral
PRNewsWire
1 month ago
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
Phase 1b/2a diSArm trial evaluated AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia Topline data anticipated in Q2 2025 to support potential future pivotal bacteremia efficacy trial LOS ANGELES , May 1, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received an additional $4.65 million of non-dilutive funding pursuant to a previously announced Department of Defense (DoD) award, received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. The award, currently totaling $26.2 million, was awarded to Armata to support clinical development of its optimized phage candidate, AP-SA02, as a potential treatment for complicated Staphylococcus aureus bacteremia (SAB).
Negative
Zacks Investment Research
1 month ago
New Strong Sell Stocks for April 28th
CCS, ARMP and CABO have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2025.
Negative
Zacks Investment Research
1 month ago
New Strong Sell Stocks for April 24th
AMPY, CARS and CLB have been added to the Zacks Rank #5 (Strong Sell) List on April 24, 2025.
Negative
Zacks Investment Research
2 months ago
New Strong Sell Stocks for April 9th
CSIQ, ARMP and DAR have been added to the Zacks Rank #5 (Strong Sell) List on April 9, 2025.
Neutral
PRNewsWire
2 months ago
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update
LOS ANGELES , March 20, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its fourth quarter and full-year ended December 31, 2024, and provided a corporate update. Fourth Quarter 2024 and Recent Developments: Announced encouraging topline results from its Phase 2 Tailwind study evaluating inhaled AP-PA02 as a potential treatment for chronic pulmonary disease; Pseudomonas aeruginosa ("P.
Charts implemented using Lightweight Charts™